Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Average Rating of “Moderate Buy” by Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been assigned an average rating of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $17.89.

A number of equities analysts have recently weighed in on the company. Piper Sandler restated an “overweight” rating and issued a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Alphatec in a research report on Friday, May 2nd. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. StockNews.com upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Finally, Barclays increased their target price on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd.

Insider Buying and Selling at Alphatec

In other news, EVP David Sponsel sold 12,946 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $10.73, for a total value of $138,910.58. Following the sale, the executive vice president now directly owns 722,128 shares of the company’s stock, valued at approximately $7,748,433.44. This represents a 1.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Scott Lish sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $12.12, for a total transaction of $145,440.00. Following the transaction, the chief operating officer now directly owns 826,251 shares of the company’s stock, valued at approximately $10,014,162.12. This represents a 1.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 126,945 shares of company stock valued at $1,416,352 in the last 90 days. 22.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alphatec

Large investors have recently added to or reduced their stakes in the business. Lido Advisors LLC raised its holdings in shares of Alphatec by 8.4% in the 4th quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company’s stock valued at $112,000 after acquiring an additional 953 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Alphatec by 0.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock valued at $2,873,000 after purchasing an additional 1,120 shares during the last quarter. Comerica Bank grew its stake in Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after buying an additional 1,248 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of Alphatec by 14.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company’s stock worth $100,000 after buying an additional 1,342 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. raised its position in shares of Alphatec by 13.4% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company’s stock valued at $133,000 after buying an additional 1,552 shares in the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Stock Performance

Shares of ATEC opened at $12.45 on Friday. The firm has a market capitalization of $1.82 billion, a P/E ratio of -9.72 and a beta of 1.06. Alphatec has a 52 week low of $4.88 and a 52 week high of $12.79. The stock has a 50 day moving average price of $10.48 and a two-hundred day moving average price of $10.00. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The company had revenue of $169.18 million for the quarter, compared to the consensus estimate of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company’s quarterly revenue was up 22.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.34) EPS. Equities analysts forecast that Alphatec will post -1.08 earnings per share for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.